The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The user discusses experiencing side effects from topical finasteride but not from oral finasteride, seeking advice on this issue. They mention a gradual increase in oral finasteride dosage with no side effects.
The conversation discusses using azelaic acid to reduce scalp inflammation while using RU58841 for hair loss. It suggests applying azelaic acid in the morning and RU58841 at night to avoid degradation, while also using dutasteride and minoxidil.
Microneedling once a week at 1mm caused bumps, possibly scars, in the treated area. The user is considering cleaning the skin before microneedling to prevent this issue.
The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
A user experienced hair thinning after taking Accutane and having a B12 deficiency. They are currently using minoxidil and beclomethasone dipropionate lotion for treatment.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
The user is seeking recommendations for scalp-friendly minoxidil and RU58841 products available in the UK, as previous products caused scalp inflammation. They mention issues with RUDirect and MinoxidilMax products.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
Seborrheic dermatitis improved after a hair transplant. Effective treatments include Sebamed Anti-Dandruff Shampoo, Vichy Anti-Dandruff Shampoo, Nizoral, and medications like finasteride, dutasteride, and minoxidil.
The user struggles to cover their entire scalp with 1 ml of RU58841 while using dutasteride and oral minoxidil for hair loss. Suggestions include using a syringe for precise application, applying twice daily, and considering the use of more than 1 ml to ensure full coverage.
A 21-year-old male used 1mg of finasteride since March with no results and suspects a scalp fungus due to pimples and burning sensations. He is seeking advice on treating the potential fungus.
An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.
The user experienced dryness and shedding with topical minoxidil and switched to oral minoxidil 2.5mg, seeking advice on what to expect. They are concerned about scalp health and looking for others' experiences with this change.
User tried oral dut 0.5mg, oral min 5mg, topical RU 80mg, and weekly microneedling at 1.5mm for hair loss. Others commented on the significant improvement and potential for future hair transplant.
The conversation discusses how to use fluridil/topilutamide with other hair loss treatments like liquid minoxidil and CB-03-01, considering fluridil's hydrophobic nature and potential degradation with water. The user questions the necessity of washing hair only once per week as suggested by the manufacturer.
Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.
The user experienced no regrowth after nine months on minoxidil and developed red bumps after starting finasteride. They also use Nizoral 2%, which helps slightly, but minoxidil causes intense itching.
User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.